Preamble to the 2015 SITC immunotherapy biomarkers taskforce

Journal for ImmunoTherapy of Cancer

Volumn 3, Issue 1, 2015, Pages

  Butterfield, Lisa H ^a,f   Disis, Mary L ^b   Fox, Bernard A ^c   Khleif, Samir N ^d   Marincola, Francesco M ^e  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d MEDICAL COLLEGE OF GEORGIA   (United States)

^e SIDRA MEDICAL AND RESEARCH CENTER   (Qatar)

^f UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Biomarkers; Clinical trial; Immune monitoring; Immunotherapy; Taskforce

Indexed keywords

BIOLOGICAL MARKER;

ANTIBODY TITER; CANCER IMMUNOTHERAPY; CARCINOGENESIS; CYTOKINE PRODUCTION; EPIGENETICS; GENOMICS; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL MONITORING; IMMUNOMODULATION; NOTE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TRANSCRIPTOMICS; TUMOR MICROENVIRONMENT;

EID: 84977100953     PISSN: None     EISSN: 20511426     Source Type: Journal    
DOI: 10.1186/s40425-015-0052-6     Document Type: Note

References (12)

1. Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA. Defining the critical hurdles in cancer immunotherapy. J Transl Med 2011, 9:214. 10.1186/1479-5876-9-214, 22168571.
2. Keilholz U, Weber J, Finke JH, Gabrilovich DI, Kast WM, Disis ML, et al. Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother 2002, 25:97-138. 10.1097/00002371-200203000-00001, 12074049.
3. Lotze MT, Wang E, Marincola FM, Hanna N, Bugelski PJ, Burns CA, et al. Workshop on cancer biometrics: identifying biomarkers and surrogates of cancer in patients: a meeting held at the Masur Auditorium, National Institutes of Health. J Immunother 2005, 28:79-119. 10.1097/01.cji.0000154251.20125.2e, 15725954.
4. Butterfield LH, Disis ML, Khleif SN, Balwit JM, Marincola FM. Immuno-oncology biomarkers 2010 and beyond: perspectives from the iSBTc/SITC biomarker task force. J Transl Med 2010, 8:130. 10.1186/1479-5876-8-130, 21138581.
5. Butterfield LH, Disis ML, Fox BA, Lee PP, Khleif SN, Thurin M, et al. A systematic approach to biomarker discovery; preamble to " the iSBTc-FDA taskforce on immunotherapy biomarkers" . J Transl Med 2008, 6:81. 10.1186/1479-5876-6-81, 19105846.
6. Butterfield LH, Palucka AK, Britten CM, Dhodapkar MV, Håkansson L, Janetzki S, et al. Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin Cancer Res 2011, 17:3064-3076. 10.1158/1078-0432.CCR-10-2234, 21558394.
7. Bedognetti D, Balwit JM, Wang E, Disis ML, Britten CM, Delogu LG, et al. SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: online resources and useful tools - a compass in the land of biomarker discovery. J Transl Med 2011, 9:155. 10.1186/1479-5876-9-155, 21929757.
8. Galon J, Pages F, Marincola FM, Thurin M, Trinchieri G, Fox BA, et al. The immune score as a new possible approach for the classification of cancer. J Transl Med 2012, 10:1. 10.1186/1479-5876-10-1, 22214470.
9. Emens LA, Silverstein SC, Khleif S, Marincola FM, Galon J. Toward integrative cancer immunotherapy: targeting the tumor microenvironment. J Transl Med 2012, 10:70. 10.1186/1479-5876-10-70, 22490302.
10. Galon J, Pagès F, Marincola FM, Angell HK, Thurin M, Lugli A, et al. Cancer classification using the Immunoscore: a worldwide task force. J Transl Med 2012, 10:205. 10.1186/1479-5876-10-205, 23034130.
11. Sunay M, Marincola F, Khleif SN, Silverstein SC, Fox BA, Galon J, et al. Focus on the target: the tumor microenvironment, Society for Immunotherapy of Cancer Annual Meeting Workshop, October 24th-25th 2012. J Immunother Cancer 2013, 1:9. 10.1186/2051-1426-1-9.
12. Hodi FS, Lee S, McDermott DF, Rao UN, Butterfield LH, Tarhini AA, et al. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. JAMA 2014, 312:1744-1753. 10.1001/jama.2014.13943, 25369488.